Prophase Labs | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 883 K

Revenue: As of FY2025 Q3, the actual value is USD 883 K, missing the estimate of USD 5.69 M.

EPS: As of FY2025 Q3, the actual value is USD -0.16.

EBIT: As of FY2025 Q3, the actual value is USD -3.215 M.

Diagnostic Services Segment

• Revenue: No revenue generated for the three and nine months ended September 30, 2025 and 2024.
• Cost of Revenue: $7,000 for the three months ended September 30, 2025, compared to $709,000 for the same period in 2024; $351,000 for the nine months ended September 30, 2025, compared to $1,429,000 for the same period in 2024.
• Operating Expenses: $1,163,000 for the three months ended September 30, 2025, compared to $1,138,000 for the same period in 2024; $2,891,000 for the nine months ended September 30, 2025, compared to $3,162,000 for the same period in 2024.
• Loss from Operations: - $1,245,000 for the three months ended September 30, 2025, compared to - $2,574,000 for the same period in 2024; - $3,856,000 for the nine months ended September 30, 2025, compared to - $6,119,000 for the same period in 2024.

Consumer Products Segment

• Revenue: $883,000 for the three months ended September 30, 2025, compared to $1,416,000 for the same period in 2024; $3,561,000 for the nine months ended September 30, 2025, compared to $5,276,000 for the same period in 2024.
• Cost of Revenue: $999,000 for the three months ended September 30, 2025, compared to $492,000 for the same period in 2024; $2,073,000 for the nine months ended September 30, 2025, compared to $3,847,000 for the same period in 2024.
• Operating Expenses: $695,000 for the three months ended September 30, 2025, compared to $1,160,000 for the same period in 2024; $1,967,000 for the nine months ended September 30, 2025, compared to $2,275,000 for the same period in 2024.
• Loss from Operations: - $1,434,000 for the three months ended September 30, 2025, compared to - $1,041,000 for the same period in 2024; - $2,714,000 for the nine months ended September 30, 2025, compared to - $2,455,000 for the same period in 2024.

Unallocated Corporate

• Operating Expenses: $4,317,000 for the three months ended September 30, 2025, compared to $3,858,000 for the same period in 2024; $8,797,000 for the nine months ended September 30, 2025, compared to $14,739,000 for the same period in 2024.
• Loss from Operations: - $4,317,000 for the three months ended September 30, 2025, compared to - $3,858,000 for the same period in 2024; - $8,797,000 for the nine months ended September 30, 2025, compared to - $14,739,000 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $7,711,000 for continuing operations for the nine months ended September 30, 2025, compared to - $8,588,000 for the same period in 2024.
• Net Cash Provided by Financing Activities: $5,956,000 for continuing operations for the nine months ended September 30, 2025, compared to $10,466,000 for the same period in 2024.

Future Outlook and Strategy

• BE-Smart™ Esophageal Pre-Cancer Diagnostic Screening Test: Commercialization planned for the first quarter of 2026, with broader insurance-backed commercialization targeted for the third quarter of 2026.
• Nebula Genomics and DNA Complete: Plans to sell whole genome sequencing products direct-to-consumers online and in retail stores, and provide testing for universities conducting genomic research.
• Equivir Clinical Trial: Final statistical analysis report expected during the fourth quarter of 2025 or the first quarter of 2026.